Effects of Exogenous Glucagon-Like Peptide-1 on the Blood Pressure, Heart Rate, Mesenteric Blood Flow, and Glycemic Responses to Intraduodenal Glucose in Healthy Older Subjects

Context:Studies relating to the cardiovascular effects of glucagon-like peptide-1 (GLP-1) and its agonists, which slow gastric emptying, have not discriminated between fasting and postprandial, blood pressure (BP) and heart rate (HR).Objective:To determine whether exogenous GLP-1 modulates the effec...

Full description

Saved in:
Bibliographic Details
Published inThe journal of clinical endocrinology and metabolism Vol. 99; no. 12; pp. E2628 - E2634
Main Authors Trahair, Laurence G., Horowitz, Michael, Hausken, Trygve, Feinle-Bisset, Christine, Rayner, Christopher K., Jones, Karen L.
Format Journal Article
LanguageEnglish
Published United States Oxford University Press 01.12.2014
Copyright by The Endocrine Society
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Context:Studies relating to the cardiovascular effects of glucagon-like peptide-1 (GLP-1) and its agonists, which slow gastric emptying, have not discriminated between fasting and postprandial, blood pressure (BP) and heart rate (HR).Objective:To determine whether exogenous GLP-1 modulates the effects of an intraduodenal (ID) glucose infusion on BP, HR, and splanchnic blood flow in healthy older subjects.Design:A double-blind randomized trial was conducted.Setting:Community-dwelling residents attended a clinical research laboratory.Patients:Ten healthy “older” subjects (9 male, 1 female; age 73.2 ± 1.5 y) were studied.Interventions:Intravenous infusion of GLP-1 (0.9 pmol/kg/min), or saline (0.9%) for 90 min (t = −30–60 min). Between t = 0–60 min, ID glucose was infused at 3 kcal/min.Main Outcome Measures:BP, HR, superior mesenteric artery (SMA) flow, blood glucose, and serum insulin were measured.Results:During the fasting period (t = −30–0 min), GLP-1 had no effect on BP or HR. In response to ID glucose (t = 0–60 min), systolic BP decreased (P < .001), and both HR (P < .001) and SMA flow (P < .05) increased, on both days. GLP-1 attenuated the maximum decrease in systolic BP (P < .05), tended to increase HR (P = .09), and increased SMA flow (P < .01). GLP-1 diminished the glycemic response (P < .05).Conclusions:In healthy older subjects, acute administration of GLP-1 attenuates the hypotensive response to ID glucose, and potentiates the increase in SMA flow.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
ISSN:0021-972X
1945-7197
1945-7197
DOI:10.1210/jc.2014-2475